Cargando…

The frequency and clinical implication of mismatch repair protein deficiency in Chinese patients with ovarian clear cell carcinoma

BACKGROUND: The aim of the present study was to assess the prevalence of deficient mismatch repair (MMR) in Chinese ovarian clear cell carcinoma (CCC) patients and its association with clinicopathologic features. METHODS: Immunohistochemistry with four antibodies against MLH1, PMS2, MSH2 and MSH6 wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Shuang, Zhou, Shuling, Zhong, Siyuan, Shan, Boer, Jiang, Wenhua, Yang, Wentao, Cai, Xu, Yang, Huijuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035241/
https://www.ncbi.nlm.nih.gov/pubmed/35461222
http://dx.doi.org/10.1186/s12885-022-09588-z
_version_ 1784693254226182144
author Ye, Shuang
Zhou, Shuling
Zhong, Siyuan
Shan, Boer
Jiang, Wenhua
Yang, Wentao
Cai, Xu
Yang, Huijuan
author_facet Ye, Shuang
Zhou, Shuling
Zhong, Siyuan
Shan, Boer
Jiang, Wenhua
Yang, Wentao
Cai, Xu
Yang, Huijuan
author_sort Ye, Shuang
collection PubMed
description BACKGROUND: The aim of the present study was to assess the prevalence of deficient mismatch repair (MMR) in Chinese ovarian clear cell carcinoma (CCC) patients and its association with clinicopathologic features. METHODS: Immunohistochemistry with four antibodies against MLH1, PMS2, MSH2 and MSH6 was performed on whole section slides, and the results were correlated with clinicopathologic variables. RESULTS: A total of 108 cases were included in the present study with a median age of 52 years at first diagnosis. Early-stage disease and platinum-sensitive recurrence accounted for 62.3 and 69.6%, respectively, of the total cases. Overall, the estimated 5-year overall survival was 70.3 and 20.7% in patients with early- and late-stage tumors, respectively. Deficient MMR was identified in 5.6% (6/108) of the cohort and included MSH2/MSH6 (n = 4) and MLH1/PMS2 (n = 2). The average age of the six patients with deficient MMR was 45.6 years, and the rate of MMR-deficient tumors in women ≤50 years was relatively higher than that in women over 50 years (10.0% vs. 2.9%; P = 0.266). Half of the patients with deficient MMR were diagnosed with synchronous (endometrial or colorectal) and metachronous (endometrial) cancer, which was significantly more than their intact counterparts (P = 0.002). All six patients with deficient MMR had early-stage tumors, and the majority (83.3%) were platinum sensitive. The median progression-free survival was slightly higher in patients with defective MMR expression than in their intact counterparts (30 months vs. 27 months), but significance was not achieved (P = 0.471). CONCLUSIONS: Young ovarian CCC patients with concurrent diagnosis of endometrial and colorectal cancer are more likely to have MMR-deficient tumors, thereby warranting additional studies to determine whether patients harboring MMR abnormalities have a favorable prognosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-09588-z.
format Online
Article
Text
id pubmed-9035241
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-90352412022-04-25 The frequency and clinical implication of mismatch repair protein deficiency in Chinese patients with ovarian clear cell carcinoma Ye, Shuang Zhou, Shuling Zhong, Siyuan Shan, Boer Jiang, Wenhua Yang, Wentao Cai, Xu Yang, Huijuan BMC Cancer Research BACKGROUND: The aim of the present study was to assess the prevalence of deficient mismatch repair (MMR) in Chinese ovarian clear cell carcinoma (CCC) patients and its association with clinicopathologic features. METHODS: Immunohistochemistry with four antibodies against MLH1, PMS2, MSH2 and MSH6 was performed on whole section slides, and the results were correlated with clinicopathologic variables. RESULTS: A total of 108 cases were included in the present study with a median age of 52 years at first diagnosis. Early-stage disease and platinum-sensitive recurrence accounted for 62.3 and 69.6%, respectively, of the total cases. Overall, the estimated 5-year overall survival was 70.3 and 20.7% in patients with early- and late-stage tumors, respectively. Deficient MMR was identified in 5.6% (6/108) of the cohort and included MSH2/MSH6 (n = 4) and MLH1/PMS2 (n = 2). The average age of the six patients with deficient MMR was 45.6 years, and the rate of MMR-deficient tumors in women ≤50 years was relatively higher than that in women over 50 years (10.0% vs. 2.9%; P = 0.266). Half of the patients with deficient MMR were diagnosed with synchronous (endometrial or colorectal) and metachronous (endometrial) cancer, which was significantly more than their intact counterparts (P = 0.002). All six patients with deficient MMR had early-stage tumors, and the majority (83.3%) were platinum sensitive. The median progression-free survival was slightly higher in patients with defective MMR expression than in their intact counterparts (30 months vs. 27 months), but significance was not achieved (P = 0.471). CONCLUSIONS: Young ovarian CCC patients with concurrent diagnosis of endometrial and colorectal cancer are more likely to have MMR-deficient tumors, thereby warranting additional studies to determine whether patients harboring MMR abnormalities have a favorable prognosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-09588-z. BioMed Central 2022-04-23 /pmc/articles/PMC9035241/ /pubmed/35461222 http://dx.doi.org/10.1186/s12885-022-09588-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ye, Shuang
Zhou, Shuling
Zhong, Siyuan
Shan, Boer
Jiang, Wenhua
Yang, Wentao
Cai, Xu
Yang, Huijuan
The frequency and clinical implication of mismatch repair protein deficiency in Chinese patients with ovarian clear cell carcinoma
title The frequency and clinical implication of mismatch repair protein deficiency in Chinese patients with ovarian clear cell carcinoma
title_full The frequency and clinical implication of mismatch repair protein deficiency in Chinese patients with ovarian clear cell carcinoma
title_fullStr The frequency and clinical implication of mismatch repair protein deficiency in Chinese patients with ovarian clear cell carcinoma
title_full_unstemmed The frequency and clinical implication of mismatch repair protein deficiency in Chinese patients with ovarian clear cell carcinoma
title_short The frequency and clinical implication of mismatch repair protein deficiency in Chinese patients with ovarian clear cell carcinoma
title_sort frequency and clinical implication of mismatch repair protein deficiency in chinese patients with ovarian clear cell carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035241/
https://www.ncbi.nlm.nih.gov/pubmed/35461222
http://dx.doi.org/10.1186/s12885-022-09588-z
work_keys_str_mv AT yeshuang thefrequencyandclinicalimplicationofmismatchrepairproteindeficiencyinchinesepatientswithovarianclearcellcarcinoma
AT zhoushuling thefrequencyandclinicalimplicationofmismatchrepairproteindeficiencyinchinesepatientswithovarianclearcellcarcinoma
AT zhongsiyuan thefrequencyandclinicalimplicationofmismatchrepairproteindeficiencyinchinesepatientswithovarianclearcellcarcinoma
AT shanboer thefrequencyandclinicalimplicationofmismatchrepairproteindeficiencyinchinesepatientswithovarianclearcellcarcinoma
AT jiangwenhua thefrequencyandclinicalimplicationofmismatchrepairproteindeficiencyinchinesepatientswithovarianclearcellcarcinoma
AT yangwentao thefrequencyandclinicalimplicationofmismatchrepairproteindeficiencyinchinesepatientswithovarianclearcellcarcinoma
AT caixu thefrequencyandclinicalimplicationofmismatchrepairproteindeficiencyinchinesepatientswithovarianclearcellcarcinoma
AT yanghuijuan thefrequencyandclinicalimplicationofmismatchrepairproteindeficiencyinchinesepatientswithovarianclearcellcarcinoma
AT yeshuang frequencyandclinicalimplicationofmismatchrepairproteindeficiencyinchinesepatientswithovarianclearcellcarcinoma
AT zhoushuling frequencyandclinicalimplicationofmismatchrepairproteindeficiencyinchinesepatientswithovarianclearcellcarcinoma
AT zhongsiyuan frequencyandclinicalimplicationofmismatchrepairproteindeficiencyinchinesepatientswithovarianclearcellcarcinoma
AT shanboer frequencyandclinicalimplicationofmismatchrepairproteindeficiencyinchinesepatientswithovarianclearcellcarcinoma
AT jiangwenhua frequencyandclinicalimplicationofmismatchrepairproteindeficiencyinchinesepatientswithovarianclearcellcarcinoma
AT yangwentao frequencyandclinicalimplicationofmismatchrepairproteindeficiencyinchinesepatientswithovarianclearcellcarcinoma
AT caixu frequencyandclinicalimplicationofmismatchrepairproteindeficiencyinchinesepatientswithovarianclearcellcarcinoma
AT yanghuijuan frequencyandclinicalimplicationofmismatchrepairproteindeficiencyinchinesepatientswithovarianclearcellcarcinoma